secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001619856-25-000040
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Q1 net loss $40M; cuts 32% workforce, extends cash runway into H2 2027
------------------------------------------------------------------------------

- Cash, equivalents & securities $212.5M as of Mar 31, 2025 (down from $249.4M at Dec 31, 2024).
- Net loss $40.0M vs $41.2M YoY; R&D expenses $35.5M (up from $33.8M) and G&A $9.7M (down from $14.6M).
- Discontinued CB-010 lupus trial, CB-012 AML trial, and preclinical work; workforce reduced ~32% with $2.5–3.5M cash costs.
- CB-010 (2L LBCL) and CB-011 (multiple myeloma) Phase 1 data expected in H2 2025 with FDA interaction for potential pivotal trial.
- Licensing revenue flat at $2.4M for the quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985625000040/0001619856-25-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985625000040/crbu-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001619856-25-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer